Author/Authors :
Mojtahedi، Zahra نويسنده Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran , , Solati Dalaki، Sharareh نويسنده Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran , , Samsami Dehaghani، Alamtaj نويسنده Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran , , Robati، Minoo نويسنده , , Monabati، Ahmad نويسنده , , Fattahi، Mohammad Javad نويسنده Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran , , Ghaderi، Abbas نويسنده ,
Abstract :
Introduction: The proto-oncogene HER2 plays a key role in the control of
cellular proliferation. Its overexpression has been reported to be associated with a
poor prognosis in cancer, particularly in breast cancer.
Materials and Methods: In the present study, serum HER2 levels were
investigated in patients diagnosed with epithelial ovarian cancer. Serum HER2
levels were detected by an ELISA commercial kit in 51 patients and 33 healthy
individuals.
Results: The mean serum HER2 level was found to be significantly higher in
patients than healthy controls (P=0.005). In 29% of patients, serum HER2 levels were
higher than the cut-off value. HER2 serum level was not associated with tumor stage
at diagnosis.
Conclusion: Elevation of HER2 in a high proportion of patients with epithelial
ovarian cancer further strengthens the importance of this molecule in the pathogenesis
of ovarian cancer.
